DE60111254T2 - Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation - Google Patents

Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation Download PDF

Info

Publication number
DE60111254T2
DE60111254T2 DE60111254T DE60111254T DE60111254T2 DE 60111254 T2 DE60111254 T2 DE 60111254T2 DE 60111254 T DE60111254 T DE 60111254T DE 60111254 T DE60111254 T DE 60111254T DE 60111254 T2 DE60111254 T2 DE 60111254T2
Authority
DE
Germany
Prior art keywords
pde5
use according
pyrazolo
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60111254T
Other languages
German (de)
English (en)
Other versions
DE60111254D1 (de
Inventor
Mitradev Sandwich BOOLELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE60111254D1 publication Critical patent/DE60111254D1/de
Application granted granted Critical
Publication of DE60111254T2 publication Critical patent/DE60111254T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60111254T 2000-11-20 2001-11-19 Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation Expired - Fee Related DE60111254T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0028245 2000-11-20
GBGB0028245.9A GB0028245D0 (en) 2000-11-20 2000-11-20 New therapeutic use
PCT/IB2001/002180 WO2002040027A1 (en) 2000-11-20 2001-11-19 Treatment of premature ejaculation

Publications (2)

Publication Number Publication Date
DE60111254D1 DE60111254D1 (de) 2005-07-07
DE60111254T2 true DE60111254T2 (de) 2006-05-04

Family

ID=9903491

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60111254T Expired - Fee Related DE60111254T2 (de) 2000-11-20 2001-11-19 Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation

Country Status (21)

Country Link
EP (1) EP1335730B1 (https=)
JP (1) JP2004520279A (https=)
KR (1) KR100595807B1 (https=)
CN (1) CN1474692A (https=)
AT (1) ATE296631T1 (https=)
AU (2) AU2002215149B2 (https=)
BR (1) BR0115413A (https=)
CA (1) CA2429114C (https=)
DE (1) DE60111254T2 (https=)
ES (1) ES2240537T3 (https=)
GB (1) GB0028245D0 (https=)
HU (1) HUP0301915A3 (https=)
IL (1) IL155521A0 (https=)
MX (1) MXPA03003586A (https=)
MY (1) MY131573A (https=)
NZ (1) NZ525167A (https=)
PL (1) PL362058A1 (https=)
PT (1) PT1335730E (https=)
TW (1) TWI280132B (https=)
WO (1) WO2002040027A1 (https=)
ZA (1) ZA200302947B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)
CN111297869A (zh) * 2020-04-23 2020-06-19 白文智 一种用于治疗早泄和勃起功能障碍的复方制剂

Also Published As

Publication number Publication date
DE60111254D1 (de) 2005-07-07
AU1514902A (en) 2002-05-27
EP1335730B1 (en) 2005-06-01
GB0028245D0 (en) 2001-01-03
ATE296631T1 (de) 2005-06-15
IL155521A0 (en) 2003-11-23
NZ525167A (en) 2005-02-25
BR0115413A (pt) 2003-10-07
JP2004520279A (ja) 2004-07-08
WO2002040027A1 (en) 2002-05-23
KR100595807B1 (ko) 2006-07-03
MXPA03003586A (es) 2003-07-14
PT1335730E (pt) 2005-09-30
PL362058A1 (en) 2004-10-18
CN1474692A (zh) 2004-02-11
CA2429114C (en) 2007-09-11
HUP0301915A3 (en) 2007-03-28
TWI280132B (en) 2007-05-01
HUP0301915A2 (hu) 2003-09-29
CA2429114A1 (en) 2002-05-23
KR20030048476A (ko) 2003-06-19
EP1335730A1 (en) 2003-08-20
ES2240537T3 (es) 2005-10-16
AU2002215149B2 (en) 2006-04-06
ZA200302947B (en) 2004-04-28
MY131573A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
US20080153841A1 (en) Treatment of premature ejaculation
DE60124972T2 (de) Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung der weiblichen sexuellen Störungen
US20050065158A1 (en) Treatment of sexual dysfunction
DE60037347T2 (de) Kombinationen enthaltend cGMP-PDE5-hemmer.
US7235625B2 (en) Multiple agent therapy for sexual dysfunction
DE69833671T2 (de) KOMBINATION AUS EINEM ALPHA-1-ADRENOREZEPTOR ANTAGONISTEN UND EINEM CGM PDEv HEMMER ZUR BEHANDLUNG VON IMPOTENZ
CA2532252A1 (en) Treatment of sexual dysfunction
AU8152301A (en) Use of PDE V inhibitors for improved fecundity in mammals
EP1125582A2 (en) Use of estrogen agonists / antagonists for the treatment of sexual dysfunction
KR20030023747A (ko) 인슐린 저항성 증후군의 치료
JPH0320219A (ja) 眼内圧降下に有用な選択性α―アドレナリン作働剤および拮抗剤の組み合わせ
DE60111254T2 (de) Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
DE69826561T2 (de) Aldose Reductase Hemmung zur Vorbeugung oder zur Umkehrung der diabetischen Kardiomyopathie
US20030055070A1 (en) Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
AU2002215149A1 (en) Treatment of premature ejaculation
DE69925312T2 (de) Bupropion zur behandlung von viralen erkrankungen
MXPA06013814A (es) Terapia de agentes multiples para la disfuncion sexual.
GB1574678A (en) Antihypertensive compositions
HK1059043A (en) Treatment of premature ejaculation
Brampton PrRAN™-SILDENAFIL
AU2004233509A1 (en) Use of PDE V inhibitors for improved fecundity in mammals
HK1105553A (en) Multiple agent therapy for sexual dysfunction

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee